Share This

Related Topics News -

     
 Title only   |   Print 
     
《大行》富瑞:從市賬率角度看藥明生物目前正處於拐點

2024-05-09T  
《大行》瑞銀降藥明生物目標價至16.6元 評級「中性」

2024-05-08T  
藥明生物回購137萬股 涉資1,983萬元

2024-05-08T  
《大行》招商證券降藥明生物評級至「中性」 削目標價至13元

2024-05-07T  
《港股》恆指高收102點 金銀股上漲 內房股回吐

2024-05-06T  
藥明生物回購190.5萬股 涉資2,488萬元

2024-04-24T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.